Rebif New Formulation + prophylactic Ibuprofen + Rebif New Formulation + ibuprofen PRN
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsing Multiple Sclerosis
Conditions
Relapsing Multiple Sclerosis
Trial Timeline
Jul 1, 2007 → Apr 1, 2008
NCT ID
NCT00619307About Rebif New Formulation + prophylactic Ibuprofen + Rebif New Formulation + ibuprofen PRN
Rebif New Formulation + prophylactic Ibuprofen + Rebif New Formulation + ibuprofen PRN is a phase 3 stage product being developed by Merck for Relapsing Multiple Sclerosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00619307. Target conditions include Relapsing Multiple Sclerosis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00619307 | Phase 3 | Completed |
Competing Products
20 competing products in Relapsing Multiple Sclerosis